Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. 1986

Y C Huang, and J L Colaizzi, and R H Bierman, and R Woestenborghs, and J Heykants

Ketoconazole is an orally effective, broad-spectrum, systemic antifungal agent. The pharmacokinetics and bioavailability of ketoconazole given as a 200-mg single dose in a tablet, suspension, or solution were studied in 24 fasting healthy males by using a crossover design. Levels of ketoconazole in plasma were determined for up to 48 h by a sensitive reverse-phase high-performance liquid chromatography method. The absorption of ketoconazole was rapid, with mean maximum concentrations of the drug in plasma of 4.2, 5.0, and 6.2 micrograms/ml attained at 1.7, 1.2, and 1.0 h, respectively, after administration of the tablet, suspension, and solution, respectively. The mean distribution and elimination half-life values were 1.5 to 1.7 and 7.5 to 7.9 h, respectively. The mean oral clearance of the solution dose was 209 (+/- 82.9 [standard deviation]) ml/min, and the mean apparent volume of distribution was 88.31 (+/- 68.72) liters. The relative bioavailabilities for the tablet and suspension were 81.2 (+/- 33.5) and 89.0 (+/- 23.1)%, respectively, of that of the solution. The data indicated the bioequivalence of the tablet to the suspension and of the suspension of the solution. Dose proportionality of ketoconazole was also studied in 12 volunteers after they received solution doses of 200, 400, and 800 mg. Linear correlations between the dose and the maximum concentration of the drug in plasma, the time to the maximum concentration, and the area under the concentration-time curve were observed. However, the increase in the area under the curve was more than proportional to the dose given. The levels in plasma seemed to decay at a lower rate after 400- and 800-mg doses. The mean oral clearance decreased from 244.9 to 123.6 and 80.0 ml/min, respectively, as the dose increased from 200 to 400 and 800 mg. The apparent dose-dependent kinetics may have been due to the presystemic elimination and capacity-limited hepatic metabolism which become saturated at higher doses.

UI MeSH Term Description Entries
D007654 Ketoconazole Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. Nizoral,R-41400,R41,400,R41400,R 41400
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

Y C Huang, and J L Colaizzi, and R H Bierman, and R Woestenborghs, and J Heykants
October 2014, Clinical drug investigation,
Y C Huang, and J L Colaizzi, and R H Bierman, and R Woestenborghs, and J Heykants
October 1990, Antimicrobial agents and chemotherapy,
Y C Huang, and J L Colaizzi, and R H Bierman, and R Woestenborghs, and J Heykants
January 2005, Clinical pharmacokinetics,
Y C Huang, and J L Colaizzi, and R H Bierman, and R Woestenborghs, and J Heykants
August 2012, Expert opinion on drug metabolism & toxicology,
Y C Huang, and J L Colaizzi, and R H Bierman, and R Woestenborghs, and J Heykants
November 2012, Cancer chemotherapy and pharmacology,
Y C Huang, and J L Colaizzi, and R H Bierman, and R Woestenborghs, and J Heykants
January 1994, European journal of clinical pharmacology,
Y C Huang, and J L Colaizzi, and R H Bierman, and R Woestenborghs, and J Heykants
July 1994, Investigative radiology,
Y C Huang, and J L Colaizzi, and R H Bierman, and R Woestenborghs, and J Heykants
September 1987, Journal of clinical pharmacology,
Y C Huang, and J L Colaizzi, and R H Bierman, and R Woestenborghs, and J Heykants
February 1986, Antimicrobial agents and chemotherapy,
Y C Huang, and J L Colaizzi, and R H Bierman, and R Woestenborghs, and J Heykants
January 2016, Clinical neuropharmacology,
Copied contents to your clipboard!